EMEND 125 mg+80 mg hard capsules
Sponsors
Karolinska University Hospital, Karyopharm Therapeutics Inc., Centre Hospitalier Universitaire Rouen
Conditions
Non-metastatic HER2-positive Breast CancerPatients with obstructive sleep apnea syndrome with arterial
hypertensionRelapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)Treatment naïve patients with MF
Phase 2
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
RecruitingCTIS2022-501504-95-00
Start: 2023-06-23Target: 402Updated: 2025-08-18
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-
Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL).
Active, not recruitingCTIS2024-513616-95-00
Start: 2020-12-22Target: 60Updated: 2025-10-02
Phase 3
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
Active, not recruitingCTIS2023-506139-13-00
Start: 2024-01-04Target: 195Updated: 2025-10-09
PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST,
APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH
OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3)
Not yet recruitingCTIS2024-514837-39-00
Target: 24Updated: 2024-07-01